The Next Wave

Darren Hickerson, Sita Somara, Almudena Martinez-Fernandez, Chi Lo, Todd Meinecke, Cynthia Wilkins-Port, Julie G. Allickson

Research output: Chapter in Book/Report/Conference proceedingChapter


Tissue engineering promises to repair or replace damaged or diseased tissues or organs. Organ shortage and transplantation complications are driving the need for autologous or immune-modulated bioengineered organs and tissues. To produce a tissue-engineered construct, one or more cell types from appropriate sources and differentiation states are identified for each organ or tissue. These cells are expanded and seeded onto biological or synthetic scaffolds to replicate the three-dimensional (3D) structure of the organ. The translation process from research bench to clinical application requires adoption of regulatory oversight specific to combinatorial therapies. Currently, numerous regenerative tissue therapies are approved by regulatory authorities or are in clinical trials or translation, with an extensive portfolio of future applications in development. 3D bioprinting promises to someday produce entire organs in one step. The nature of the personalised medicine approach in tissue engineering presents a challenge for manufacturing, scale up and funding.

Original languageEnglish (US)
Title of host publicationSecond Generation Cell and Gene-Based Therapies
Subtitle of host publicationBiological Advances, Clinical Outcomes and Strategies for Capitalisation
Number of pages26
ISBN (Electronic)9780128120347
ISBN (Print)9780128120330
StatePublished - Jan 1 2020


  • Aseptic manufacturing
  • Bioengineering
  • Cellular therapy
  • Clinical translation
  • Commercialisation
  • Organ transplant
  • Regenerative medicine
  • Tissue engineering
  • Tissue-engineered organ

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'The Next Wave'. Together they form a unique fingerprint.

Cite this